-+ 0.00%
-+ 0.00%
-+ 0.00%

REGENXBIO Announces Closure Of Non-Dilutive, Limited Recourse Royalty Bond Agreement Of Up To $250M With Healthcare Royalty

Benzinga·05/19/2025 20:08:15
Listen to the news
  • $150 million secured at closing extends cash runway into early 2027
  • REGENXBIO retains additional potential non-dilutive funding opportunities, including monetization of Priority Review Voucher (PRV) and milestones from AbbVie

ROCKVILLE, Md., May 19, 2025 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced the closure of a non-dilutive, limited recourse royalty bond agreement of up to $250 million with Healthcare Royalty (HCRx). This agreement monetizes select anticipated royalties and milestones, and provides both immediate and expected future, non-dilutive capital.  REGENXBIO received $150 million at closing, extending the Company's expected cash runway into early 2027.